



SMS PHARMACEUTICALS LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad, Telangana State - 500 096

CIN :L24239AP1987PLC008066, Email:info@smspharma.com, www.smspharma.com

Un-Audited Financial Results for the Quarter and Six months Ended 30th September, 2015

(Rs.in Lakhs)

S. No	Particulars	Quarter Ended		Half Year Ended		Year Ended
		30-09-2015	30-06-2015	30-09-2014	30-09-2014	31-03-2015
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations					
	(a) Net sales/Income from Operations	14,183.82	11,322.30	12,617.90	25,506.12	53,604.12
	(b) Other Operating Income	1,089.53	1,072.89	882.94	2,162.42	4,324.46
	Total Income from Operations (net)	15,273.35	12,395.19	13,500.84	27,668.54	57,928.58
2	Expenses					
	(a) Cost of materials consumed	10,728.71	8,123.97	9,343.71	18,852.68	38,841.06
	(b) Purchases of stock-in-trade	-	-	4.87	-	21.77
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	(727.89)	(256.77)	(138.97)	(984.67)	214.91
	(d) Employee Benefits Expense	928.31	882.02	736.81	1,810.33	3,167.13
	(e) Depreciation and amortisation expense	474.09	465.26	408.49	939.35	1,716.61
	(f) Other expenses	2,088.40	1,852.06	1,989.40	3,940.47	7,587.58
	Total - (a to f)	13,491.62	11,066.54	12,344.31	24,558.16	51,019.13
3	Profit from Operations before Other Income, finance cost and Exceptional Items (1) - (2)	1,781.73	1,328.65	1,156.53	3,110.38	6,909.45
4	Other Income	18.92	38.97	65.94	57.89	1,631.99
5	Profit / (Loss) from ordinary activities before finance costs and exemptional items (3)+(4)	1,800.65	1,367.62	1,222.47	3,168.27	8,541.44
6	Finance costs	431.82	447.83	407.96	879.65	1,793.09
7	Profit / (Loss) from ordinary activities after finance costs but before exemptional items (5) + (6)	1,368.83	919.79	814.51	2,288.62	6,748.35
8	Exceptional items	-	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before Tax (7) + (8)	1,368.83	919.79	814.51	2,288.62	6,748.35
10	Tax Expenses	320.00	200.00	300.00	520.00	3,223.90
11	Net Profit / (Loss) from ordinary activities after Tax (9)-(10)	1,048.83	719.79	514.51	1,768.62	3,524.45
12	Extraordinary items (net of Tax Expense Rs. ... in lakhs)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11) -(12)	1,048.83	719.79	514.51	1,768.62	3,524.45
14	Share of profit / (loss) of associates*					
15	Minority Interest*					
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	1,048.83	719.79	514.51	1,768.62	3,524.45
17	Paid-up equity share capital Rs.10/- per share	846.52	846.52	846.52	846.52	846.52
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	24,629.48
19.i	Earning Per Share (before extraordinary items) (of Rs...../ each) (not annualised)	12.39	8.50	6.08	20.89	41.63
	(a) Basic					
	(b) Diluted					
19.ii	Earning Per Share (after extraordinary items) (of Rs...../ each) (not annualised)	12.39	8.50	6.08	20.89	41.63
	(a) Basic					
	(b) Diluted					

A	PARTICULARS OF SHARE HOLDING					
1	Public Shareholding					
	- Number of Shares	2,965,018	3,054,760	3,054,760	2,965,018	3,054,760
	- Percentage of Shareholding	35.01	36.09	36.09	35.01	36.09
2	Promoters and Promoters Group Shareholding**					
a)	Pledged/Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
b)	Non-encumbered	5,500,185	5,410,443	5,410,443	5,500,185	5,410,443
	- Number of Shares					
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100
	- Percentage of Shares (as a % of the total share capital of the company)	64.99	63.91	63.91	64.99	63.91

	Particulars	3 Months ended 30-09-2015
B.	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	Nil

Statement of Assets & Liabilities as at 30th September, 2015

Sr. No.	Particulars	As at 30-09-2015 (Unaudited)	As at 31.03.2015 Audited
A	<u>EQUITY AND LIABILITIES</u>		
1	Shareholders' Funds		
	(a) Share Capital	846.52	846.52
	(b) Reserves & Surplus	26,398.11	24,629.48
	Sub-Total -Shareholders' funds	27,244.63	25,476.00
2	Non-Current Liabilities		
	(a) Long Term Borrowings	10,741.22	8,228.63
	(b) Deferred Tax Liability (Net)	3,572.81	3,572.81
	(c) Long Term Provisions	288.95	288.95
	Sub-Total -Non-Current Liabilities	14,602.98	12,090.39
3	Current Liabilities		
	(a) Short Term Borrowings	6,833.06	6,984.55
	(b) Trade Payables	6,011.21	6,100.08
	(c) Other Current Liabilities	2,238.39	2,326.26
	(d) Short Term Provisions	2,223.77	1,144.44
	Sub-Total - Current Liabilities	17,306.43	16,555.33
	TOTAL - EQUITY AND LIABILITIES	59,154.04	54,121.72
B	<u>ASSETS</u>		
1	Non-Current Assets		
	(a) Fixed Assets	33,138.22	30,596.91
	(b) Non Current Investments	1,639.31	1,322.81
	(c) Long Term Loans & Advances	2,067.72	1,922.78
	Sub-Total - Non-Current Assets	36,845.25	33,842.50
2	Current Assets		
	(a) Inventories	9,334.66	8,602.05
	(b) Trade Receivables	6,334.18	5,920.17
	(c) Cash and Cash Equivalents	716.31	636.37
	(d) Short Term Loans & Advances	278.97	1,062.41
	(e) Other Current Assets	5,644.66	4,058.22
	Sub-Total - Current Assets	22,308.79	20,279.22
	TOTAL ASSETS	59,154.04	54,121.72

Notes:

- The above results were reviewed by the Audit Committee on 7th November, 2015 and taken on record by the Board of Directors at its meeting held on 7th November, 2015 and "Limited Review" of the same has been carried out by the Statutory Auditors of the company.
- The Company's business activity falls within a single primary business segment. Hence segment reporting is not applicable.
- The effect of deferred tax will be considered at the end of the year.
- All accounting policies are followed consistently.
- Figures of previous periods have been regrouped / rearranged wherever necessary.

BY Order of the Board
SMS Pharmaceuticals Ltd

Place: Hyderabad
Date: 07-11-2015

N.Rajendra Prasad
Chief Financial Officer